List view / Grid view
27 October 2014 | By Clinuvel Pharmaceuticals Limited
The first new pharmaceutical drug invented and developed for an untreated disorder by any Australian company has received regulatory approval from the European Medicines Agency (EMA). SCENESSE® (afamelanotide 16mg) treats the debilitating genetic disorder porphyria (EPP), or absolute intolerance to sunlight...
24 October 2014 | By Probiodrug
Probiodrug AG announces the successful completion of its Initial Public Offering, which was launched on 10 October 2014 (the “IPO” or the “Offering”)...
24 October 2014 | By electroCore
Preliminary results of an open-label trial carried in the journal of Headache and Pain reported that a single treatment with electroCore’s hand held non-invasive vagus nerve stimulation (nVNS) device gammaCore, completely resolved 44.8% of migraines within 30 minutes...
24 October 2014 | By European Medicines Agency
Rapid scientific advice to speed up development...
24 October 2014 | By GlaxoSmithKline
GSK announces Q3 core EPS of 27.9p +5% CER excluding divestments and dividend of 19 pence per share...
24 October 2014 | By GlobalData
The recent termination of AbbVie’s deal to acquire Shire makes this pharmaceuticals’ first major casualty of new US tax inversion legislation, and has jolted the industry out of its reverie, according to an analyst with research and consulting firm GlobalData.
24 October 2014 | By Helsinn Group
Helsinn Group, the company focused on building quality cancer care, present data at the International Society of Paediatric Oncology (SIOP) congress establishing that palonosetron, at a dose 20 μg/kg, is a valuable and efficacious treatment option for chemotherapy-induced nausea and vomiting (CINV) in pediatric patients up to 17 years of…
23 October 2014 | By MRC Press Office
The Chancellor of the Exchequer, George Osborne, has announced that a partnership led by the Medical Research Council will invest over £230 million in a range of revolutionary technologies aimed at identifying the causes of diseases such as cancer and dementia, and dramatically speeding up diagnosis and treatment...
23 October 2014 | By Cardio3 BioSciences
Cardio3 BioSciences announces the appointment of Dr. Warren Sherman as Chief Medical Officer, effective as of 1 November 2014...
23 October 2014 | By Masters Speciality Pharma
Masters Speciality Pharma is pleased to announce a partnership agreement with Speciality European Pharma for the exclusive distribution of Mitocin®/Mitem® (mitomycin) to the Caribbean, Egypt, Kuwait, Iran, Saudi Arabia, UAE, Kenya, Seychelles, Uganda, Zimbabwe, Chile, Denmark, Greece, Ireland, Norway and Sweden...
23 October 2014 | By Santen
Santen GmbH. announced the positive outcome of the Decentralized Procedure (DCP) for TAPTIQOM® in Europe...
23 October 2014 | By Frost & Sullivan
Strong relationships with end users and an effective post sales service strategy must be a priority for wound care companies, says Frost & Sullivan...
22 October 2014 | By Distributed by APO (African Press Organization) on behalf of Rotary International
With a 90 percent reduction in polio cases, Nigeria is close to ending transmission of the poliovirus...
22 October 2014 | By GlobalData
The recent US Food and Drug Administration approval of Harvoni (ledipasvir/sofosbuvir), Gilead Sciences’ once-daily, single-tablet regimen to treat chronic hepatitis C virus (HCV) genotype 1 (GT1) infection in adults, will enable the company to maintain its dominance in an increasingly competitive market...
22 October 2014 | By NYU Langone Medical Center
Researchers at NYU Langone Medical Center and elsewhere say that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia...
